Humadx Secures Over RMB 100 Million in Series A Financing to Accelerate Innovation in Flow Fluorescence Technology

VCBeat recently learned that,Nanjing Human Zhizao Technology Co., Ltd. (hereinafter referred to as “Human Zhizao”) completed its Series A2 financing in the first quarter of this year., this round of financing was led byWenrun InvestmentandSunland CapitalJoint Investment.This marks a rapid new round of financing for Nanjing Human Zhizao Technology Co., Ltd., following its A1 round led exclusively by Yuan Sheng Venture Capital at the end of last year, bringing the company’s total Series A funding to over RMB 100 million.

This financing round reflects the capital market’s strong interest in flow fluorescence technology, as well as its full confidence in the strength, technological accumulation, and product progress of the Nanjing Human Zhizao Technology Co., Ltd. team.The proceeds from this financing round will be primarily used to expand the commercialization of Nanjing Human Zhizao Technology Co., Ltd.'s independently developed fully automated flow fluorescence detection platform, advance product registration and clinical validation, and enhance the density of talent within the team. Qiangyun Capital continues to serve as the exclusive financial advisor for this financing round.

HumaPlex 1200 Fully Automated Flow Cytometry Fluorescence Detection Platform

Flow Fluorescence Detection Technology is a new generation of high-throughput, multi-analyte simultaneous detection technology and currently represents one of the most prominent sectors in the field of in vitro diagnostics (IVD). Characterized by high throughput, high sensitivity, a wide linear range, and excellent reproducibility, flow fluorescence technology offers performance comparable to chemiluminescence immunoassays (CLIA), while providing even higher detection throughput and lower overall costs.

Flow fluorescence technology enables the simultaneous detection of dozens of indicators within a single reaction system. Consequently, multi-analyte testing can be completed using only one set of reagents and consumables, significantly reducing testing costs for clinical users compared to chemiluminescence. Against the backdrop of rising domestic testing demand, coupled with medical insurance cost containment and healthcare reform, flow fluorescence technology meets laboratories’ needs for cost reduction and quality improvement, aligning with the development trends of medical laboratory science in China.

Driven by both national policies and market demand, Nanjing Human Zhizao Technology Co., Ltd. has established a comprehensive layout across the entire industry chain for flow fluorescence technology. The company has achieved independent research and development as well as iterative upgrades of key raw materials, specifically magnetic coded microspheres; obtained medical device registration certificates for fully automated flow fluorescence detection instruments and their accompanying reagents; and completed nationwide coverage of its marketing network. It is one of the few enterprises in China to have achieved full integration of the flow fluorescence industry chain.

Centered on its ultra-high-speed flow fluorescence immunoassay platform, Human Zhizao is committed to providing multi-tiered immunodiagnostic solutions for laboratories at all levels. The founding team of Human Zhizao has been deeply engaged in the in vitro diagnostics (IVD) industry for over a decade. Starting from the Chinese branch of a German enterprise, the team has thoroughly explored the autoantibody testing market, established close collaborations with numerous experts, and accumulated extensive channel resources. Based on precise analysis and control of technological trends and market demands, Human Zhizao focuses on the flow fluorescence sector, adhering to German standards for quality assurance while leveraging Chinese speed for rapid iteration and upgrades, aiming to meet the ever-evolving needs of domestic customers.

Currently, the HumaPlex 1200 Fully Automated Flow Fluorescence Detection Platform and its配套 ANCA autoantibody detection kit, as well as the HumaBlot 72FA Fully Automated Immunoblotting Analyzer and its配套 ANCA autoantibody detection kit, both independently developed by Human Zhizao, have obtained medical device registration certificates issued by the Beijing Medical Products Administration. These products provide testing solutions for end users with diverse needs.

HumaBlot 72FA Fully Automated Immunoblotting System

The core founding team of Nanjing Human Zhizao Technology Co., Ltd. has many years of work experience in multinational IVD companies, with a broad international perspective, so overseas business is also one of the key focuses of Human Zhizao. As of now, Human Zhizao has obtained more than 100 CE registration certificates and completed registration access in many countries. As an innovative R&D and production enterprise, the rapid development of Human Zhizao has also attracted much attention from many overseas companies. It is reported that Human Zhizao will soon reach deep cooperation agreements with several long-established European IVD companies for the overseas market.

The rapidly expanding Chinese market remains the core foundation for Human Zhizao. During this round of financing, Human Zhizao completed the acquisition of Eurasia Pioneer Biotechnology Investment (Beijing) Co., Ltd. (“Eurasia Pioneer”) and integrated it into its marketing center. Established in 2015, Eurasia Pioneer has long served as a commercial partner in China for multiple European IVD companies and possesses systematic marketing capabilities. This integration further strengthens Human Zhizao’s national marketing team, significantly enhancing its sales and channel expansion capabilities, thereby providing robust support for the promotion of its self-developed products.

Flow cytometry-based fluorescence technology has attracted widespread attention within the industry due to its unique technical characteristics and broad application prospects. Nanjing Human Zhizao Technology Co., Ltd. has taken a pioneering position in this field, holding independent intellectual property rights for its core technology of multiplex magnetic encoding microspheres. Driven by genuine clinical needs, the company’s core products are all scheduled to obtain medical device registration certificates and be launched on the market in 2023. By focusing intensively on the field of autoantibody detection, the company strives to become a leading enterprise in the flow cytometry-based fluorescence sector.

Regarding this round of financing,Mr. Li Dongqi, Founder of Human ZhizaoStatement: We extend our gratitude to Wenrun Investment, Sunland Capital, and existing shareholders for their choice and trust in Human Zhizao. We also thank our team for their diligent work in demonstrating value and ensuring the successful completion of the Company’s Series A financing round in the short term. The Chinese in vitro diagnostics (IVD) market is undergoing profound changes. In the coming years, alongside the recovery of the national economy, the IVD sector boasts a bright outlook, with continued expansion in market capacity. The dividends from the traditional chemiluminescence market, defined by foreign manufacturers over the past two decades, are gradually fading. Human Zhizao’s multiplex flow fluorescence technology can significantly reduce the cost per test result and enhance laboratory operational efficiency, making it a robust technology well-suited to China’s specific conditions.

Nanjing Human Zhizao Technology Co., Ltd. remains firmly focused on the flow fluorescence sector, regarding quality as the company’s foundational “one.” It adheres to defining products from the customer’s perspective, progressively opens its platform for external collaborations, solidifies its core business, and pursues differentiation. The company’s strategy is being systematically implemented along its development timeline.

Dr. Wang Yingbao, Wenrun InvestmentStatement: We firmly believe in the promising prospects of flow fluorescence technology in the field of in vitro diagnostics, and we are confident that the experienced team at Nanjing Human Zhizao Technology Co., Ltd. will continue to expand new clinical application scenarios in the field of flow fluorescence. With the continuous enrichment of treatment methods, the market for autoantibody and allergen testing is developing rapidly, and the trend of iterative development in testing technologies is becoming more pronounced. Recently, the company has completed the integration of its R&D and sales departments, and we believe that more innovative products closely aligned with market demands will be launched in the future. We are delighted to become shareholders of Nanjing Human Zhizao Technology Co., Ltd. and honored to accompany the company on its journey of growth.

Mr. Duan Yun, Sunland CapitalShanghai Sunland Investment Management Co., Ltd. (“Sunland Capital”) has closely monitored flow fluorescence, a promising technology in the field of in vitro diagnostics (IVD). Nanjing Human Zhizao Technology Co., Ltd. (“Human Zhizao”) has assembled a comprehensive team covering microspheres, reagents, and instruments. Its core products have obtained certification from the National Medical Products Administration (NMPA) and achieved stable mass production, establishing a distinct competitive advantage in the market. Beyond its technological platform, Human Zhizao has strategically entered the fields of autoantibodies and allergens, a choice that aligns closely with market opportunities and the team’s background, thereby laying a solid foundation for rapid commercialization. Sunland Capital is committed to investing in outstanding medical device and IVD companies that meet China’s healthcare needs. We are confident in the growth prospects of Human Zhizao under the leadership of Mr. Li.

Ms. Yan Guopei, Qiangyun CapitalStatement: The flow cytometry fluorescence sector selected by Nanjing Human Zhizao Technology Co., Ltd. holds significant promise, with its product R&D and regulatory registration progress leading the industry. The team possesses comprehensive capabilities and an admirable spirit of dedication. In particular, we are highly optimistic about the core team represented by Mr. Li. Leveraging nearly 20 years of experience in the IVD industry, they have developed a highly competitive strategic framework in technological prospects, product iteration, and market expansion, providing robust support for the achievement of the company’s various milestones.

Nanjing Human Zhizao Technology Co., Ltd. is a medical technology innovation company integrating research and development, production, and sales. Leveraging years of accumulated expertise in materials science, in vitro diagnostics (IVD), and marketing, and centered on flow fluorescence technology, the company is committed to providing clinical customers with automated, high-throughput, and highly competitive fully automatic flow fluorescence detection platforms and supporting reagents. It focuses on the diagnosis of major immune diseases, complex and refractory conditions, and rare diseases, while actively expanding into emerging blue-ocean markets within the IVD sector.

Wenrun Investment is committed to building a leading private equity investment management institution in China that is industrialized, market-oriented, and boutique-style. Its core investment management team was established in 2011 and comprises a high-caliber elite group with over a decade of investment management experience and professional, steady investment capabilities, having achieved consistent outstanding performance over the years. Leveraging the strong industrial background of Wens Foodstuff Group and continuing its industrial heritage, Wenrun Investment focuses on sectors such as hard technology, pharmaceuticals, and major consumer goods. Notable portfolio companies managed by the firm include Desano Pharmaceutical, Genetron Biology, Auscan, BioBase, Dengkang Oral Care, Kangsheng Biotechnology, Shimai Pharmaceutical, Triangle Defense, Sailun Tire, Baiya Shares, Intretech, Shunbo Alloy, AVIC Heavy Machinery, and Nanjing Xuankai.

Sunland Capital is a professional fund focused on early-stage investments in the healthcare industry, targeting high-growth segments such as innovative medical devices (in vitro diagnostics and gene technologies, minimally invasive interventions, implantable devices, minimally invasive surgical instruments, and medical robotics), innovative biopharmaceuticals, life sciences, and healthcare services. The core team of Sunland Capital comprises founders of publicly listed healthcare companies, as well as professionals specializing in the medical and pharmaceutical industries, finance, and strategic investment. The firm provides value-added services to its portfolio companies in areas including strategy formulation, talent acquisition, R&D, marketing, legal and regulatory compliance, mergers and acquisitions, IPOs, and industry association resources. It also assists portfolio companies in integrating advanced international technologies and establishing international operational concepts and standards, thereby driving their continuous innovation and development.